NAD+ (Nicotinamide adenine dinucleotide) for Injection recall — Class I (D-0094-2026) · pharmaranks
Class IOngoing
NAD+ (Nicotinamide adenine dinucleotide) for Injection recall
FDA recall D-0094-2026 · initiated Jul 30, 2025
Most serious — a reasonable probability that use will cause serious harm or death.
Why it was recalled
Microbial Contamination of Sterile Products: elevated endotoxin levels
Details
Product
NAD+ (Nicotinamide adenine dinucleotide) for Injection, a) 100 mg/mL b) 200 mg/mL, 10 mL multi-dose amber vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692.
Recalling company
GenoGenix LLC
Classification
Class I
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
US Nationwide.
Initiated
Jul 30, 2025
FDA report date
Oct 15, 2025
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.